Jianping Xiong

12.6k total citations · 4 hit papers
189 papers, 5.0k citations indexed

About

Jianping Xiong is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jianping Xiong has authored 189 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Molecular Biology, 76 papers in Oncology and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jianping Xiong's work include Cancer-related molecular mechanisms research (31 papers), RNA modifications and cancer (26 papers) and Cancer Immunotherapy and Biomarkers (24 papers). Jianping Xiong is often cited by papers focused on Cancer-related molecular mechanisms research (31 papers), RNA modifications and cancer (26 papers) and Cancer Immunotherapy and Biomarkers (24 papers). Jianping Xiong collaborates with scholars based in China, United States and Australia. Jianping Xiong's co-authors include Jun Deng, Xiaojun Xiang, Junhe Li, Leizhen Zheng, Shukui Qin, Yuxian Bai, Jun Chen, Shanshan Huang, Ling Zhang and T. Suarez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Cell Biology.

In The Last Decade

Jianping Xiong

178 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

2009 582 citations Jianping Xiong et al. profile →
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

2020 418 citations Zhiqiang Meng, Jianping Xiong et al. profile →
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

2013 417 citations Jianming Xu, Jianping Xiong et al. Journal of Clinical Oncology profile →
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

2018 326 citations Jianping Xiong et al. profile →

Peers

Jianping Xiong

ONCOL

PRM

SURGE

Ferdinando De Vita Italy

Matthias P. Ebert Germany

Seung Tae Kim South Korea

David S. Shames United States

Tetsuji Sawada Japan

Nobuhiko Tanigawa Japan

E. Gabriela Chiorean United States

Teresa Troiani Italy

Hirotaka Konishi Japan

Jing‐Ping Yun China

Ferdinando De Vita Italy

Jianping Xiong

2.0k ×0.9

3.4k ×1.7

ONCOL

2.2k ×1.3

PRM

1.0k ×0.8

1.2k ×1.5

SURGE

Citations per year, relative to Jianping Xiong Jianping Xiong (= 1×) peers Ferdinando De Vita

Countries citing papers authored by Jianping Xiong

Since Specialization

Citations

This map shows the geographic impact of Jianping Xiong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianping Xiong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianping Xiong more than expected).

Fields of papers citing papers by Jianping Xiong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianping Xiong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianping Xiong. The network helps show where Jianping Xiong may publish in the future.

Co-authorship network of co-authors of Jianping Xiong

This figure shows the co-authorship network connecting the top 25 collaborators of Jianping Xiong. A scholar is included among the top collaborators of Jianping Xiong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianping Xiong. Jianping Xiong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xiong, Jianping, L. Liu, Yu Wei, et al.. (2025). Efficiently scaled-up production of recombinant human elastin-like polypeptides using multiple optimization strategies. Journal of Biotechnology. 401. 32–47. 1 indexed citations

Le, Yi, Ling Zhou, Yan He, et al.. (2025). SNX5 facilitates the progression of gastric cancer by increasing the membrane localization of LRP5. Oncogene. 44(17). 1182–1196. 1 indexed citations

Chen, Jingyi, Wen Qin, Wei Jin, et al.. (2025). TMEM160 inhibits KEAP1 to suppress ferroptosis and induce chemoresistance in gastric cancer. Cell Death and Disease. 16(1). 287–287. 3 indexed citations

Liang, Xiaoyu, et al.. (2025). Iminodiacetic acid functionalized sodium alginate: An efficient Al-chelating adsorbent for fluoride removal. Separation and Purification Technology. 375. 133652–133652.

Li, Xuan, Qianqian Shi, Wen Qin, et al.. (2024). YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression. Cellular and Molecular Life Sciences. 81(1). 143–143. 2 indexed citations

Zhong, Min, Ling Zhou, Yun-Zheng Le, et al.. (2024). SPIN1 accelerates tumorigenesis and confers radioresistance in non-small cell lung cancer by orchestrating the FOXO3a/FOXM1 axis. Cell Death and Disease. 15(11). 832–832. 1 indexed citations

Dai, Xiaofeng, et al.. (2024). MDM2 inhibitors in cancer immunotherapy: Current status and perspective. Genes & Diseases. 11(6). 101279–101279. 10 indexed citations

Yu, Xin, et al.. (2023). Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via the cAMP-CREB axis. Discover Oncology. 14(1). 17–17. 9 indexed citations

Zhou, Ling, Hui Guo, Quan Liao, et al.. (2023). miR‐3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi‐targets. Journal of Cellular and Molecular Medicine. 27(20). 3090–3106. 4 indexed citations

10.

Zou, Jian‐Ping, Ling Zhou, Yi Le, et al.. (2023). WWP2 drives the progression of gastric cancer by facilitating the ubiquitination and degradation of LATS1 protein. Cell Communication and Signaling. 21(1). 38–38. 19 indexed citations

11.

Wu, Zhenzhi, Jing Zhang, Rongzhen Zhao, et al.. (2023). BIDL: a brain-inspired deep learning framework for spatiotemporal processing. Frontiers in Neuroscience. 17. 1213720–1213720.

12.

Xu, Jianming, Jianping Xiong, Shanzhi Gu, et al.. (2023). A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.. Journal of Clinical Oncology. 41(16_suppl). e16118–e16118. 1 indexed citations

13.

Yao, Yangyang, Zhen Liu, Shanshan Huang, et al.. (2022). The E3 ubiquitin ligase, FBXW5, promotes the migration and invasion of gastric cancer through the dysregulation of the Hippo pathway. Cell Death Discovery. 8(1). 79–79. 32 indexed citations

14.

Zhou, Ling, Heng Wang, Min Zhong, et al.. (2022). The E3 Ubiquitin Ligase TRIM11 Facilitates Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway via Destabilizing Axin1 Protein. Journal of Oncology. 2022. 1–14. 14 indexed citations

15.

Qin, Shukui, Shanzhi Gu, Zhenggang Ren, et al.. (2021). Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. International Journal of Cancer. 149(11). 1944–1954. 38 indexed citations

16.

Wu, Xiaoyan, Xiang Wang, Gelin Xu, et al.. (2020). Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients with Gallbladder Carcinoma. SHILAP Revista de lepidopterología. 1 indexed citations

17.

Huang, Shanshan, Yuan Cao, Hui Guo, et al.. (2020). Up‐regulated acylglycerol kinase (AGK) expression associates with gastric cancer progression through the formation of a novel YAP1‐AGK–positive loop. Journal of Cellular and Molecular Medicine. 24(19). 11133–11145. 13 indexed citations

18.

Xiong, Jianping, et al.. (2017). Patterns of recurrence and outcomes in patients with luminal breast cancer: a retrospective study.. PubMed. 38(1). 14–19. 1 indexed citations

19.

Hunt, Margie, Hai Pham, Rajesh Regmi, et al.. (2016). Simultaneous MV‐kV imaging for intrafractional motion management during volumetric‐modulated arc therapy delivery*. Journal of Applied Clinical Medical Physics. 17(2). 473–486. 25 indexed citations

20.

Xiang, Xiaojun, Jun Deng, Yawen Liu, et al.. (2015). MiR-1271 Inhibits Cell Proliferation, Invasion and EMT in Gastric Cancer by Targeting FOXQ1. Cellular Physiology and Biochemistry. 36(4). 1382–1394. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact